Sarah Newell

Sarah Newell

Auto-generated profile, based on publicly available information

Sarah Newell

Bicycle Tx Ltd, Blocks A&B, Portway Building, Granta Park, Great Abington, Cambridge, UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SAShenaz Allyjaun
Shenaz Allyjaun
EDEmily Dunbar
Emily Dunbar
SHSteven W. Hardwick
Steven W. Hardwick
SNSarah Newell
Sarah Newell
FHFinn Holding
Finn Holding
HNHector Newman
Hector Newman
The lipopolysaccharide (LPS) transport (Lpt) system in Gram-negative bacteria maintains the integrity of the asymmetric bacterial outer membrane (OM). LPS biogenesis systems are essential in most Gram-negative bacteria, with LptDE responsible for the delivery of LPS to the outer leaflet of the OM. As an externally accessible, essential protein, LptDE offers a promising target for inhibitor development without the need for cellular penetration. However, there are no direct inhibitors of E. coli LptDE, and drug discovery is made challenging since it is a membrane target without a conventional active site. Here, the bicycle phage display platform was used in combination with cryogenic-electron microscopy (cryo-EM) and surface plasmon resonance to identify and map bicyclic peptide binders to Shigella flexneri LptDE (SfLptDE). Four distinct epitopes with unique bicycle molecule binding motifs were identified across the SfLptD β-barrel. This method represents a streamlined workflow for the identification and prioritization of hit molecules against LptDE.

10 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJonathan R. Whiteside
Jonathan R. Whiteside
NLNick Lewis
Nick Lewis
LDLaura Díaz-Sáez
Laura Díaz-Sáez
HNHector Newman
Hector Newman
SNSarah Newell
Sarah Newell
CRCatherine E. Rowland
Catherine E. Rowland
α-Hemolysin (Ahly) is a major Staphylococcus aureus virulence determinant implicated in tissue injury and immune dysregulation; antibody inhibitors have reached clinical trials but alternatives with improved ease of manufacture and tissue penetration are desirable. Here we demonstrate that phage-derived bicyclic peptides can serve as compact, chemically tractable Ahly neutralisers. Using TATB-scaffolded M13 phage libraries we identified WNP-motif containing bicyclic binders, with a lead hit of Peptide 14 (K D = 1792nM) and progressed the lead by iterative affinity maturation to Peptide 20 (K D = 609 nM) and by incorporation of strategically chosen non-canonical amino acids to yield Peptide 88 (KD = 96 nM). A 2.2 Å co-crystal structure with AhlyH35A locates the binding footprint on the rim domain and explains the critical role of the WNP motif in target engagement. Functional assays show that the Peptide 88 blocks Ahly mediated hemolysis, inhibits Ahly driven ADAM10 activation, and elucidate its inhibitory mechanism of preventing Ahly binding to human A549 epithelial cells. Peptide 88 protects A549 cells from recombinant toxin and attenuates cytotoxicity in S. aureus co-culture experiments, whilst showing no toxicity to A549 cells. Bicyclic peptides thus represent a new and promising anti-virulence modality: small, synthetically accessible molecules that mimic antibody recognition, with therapeutic potential against S. aureus infections.